Unicycive Therapeutics Inc. Announces $50 Million Private Placement: Here's What It Means for You. Unicycive Therapeutics Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company, announced on March 14, 2024, that it has secured a $50 million private placement from undisclosed investors. This news could have significant implications for the company's ongoing research and development efforts, and it may affect future inves...
Unicycive Therapeutics' UNI-494 Granted Orphan Drug Designation by FDA: A Leap Forward for Kidney Transplant Patients. In a landmark development within the medical field, Unicycive Therapeutics (NASDAQ:UNCY) recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its drug candidate, UNI-494. This groundbreaking compound is being developed specifically for the prevention of Delayed G...
$Unicycive Therapeutics(UNCY.US)$Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the US Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients Benzinga· 2 mins ago
Unicycive Therapeutics股票討論區
$50 Million Private Placement Announces By Clinical-stage Biotech Company
Unicycive Therapeutics Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company, announced on March 14, 2024, that it has secured a $50 million private placement from undisclosed investors. This news could have significant implications for the company's ongoing research and development efforts, and it may affect future inves...
Nice! Boom!
Update
Orphan Drug Designation Granted By FDA For Major Medical Company
In a landmark development within the medical field, Unicycive Therapeutics (NASDAQ:UNCY) recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its drug candidate, UNI-494. This groundbreaking compound is being developed specifically for the prevention of Delayed G...
News
Benzinga· 2 mins ago
APLM Warrants price target of 11.50 found in 424B3 filing
$盛德財富(PWM.US)$$Guardforce AI(GFAI.US)$$Intuitive Machines(LUNR.US)$$Amesite(AMST.US)$$Tenax Therapeutics(TENX.US)$ $Buzzfeed(BZFD.US)$$COMSovereign(COMS.US)$$Minerva Surgical(UTRS.US)$$Ault Alliance(AULT.US)$$尚乘數科(HKD.US)$$Micromobility.com(MCOM.US)$$Cadrenal Therapeutics(CVKD.US)$$Genius Group(GNS.US)$$BBBYQ$$Cosmos Health(COSM.US)$$Panbela Therapeutics(PBLA.US)$$APGN$$Annexon(ANNX.US)$$金太陽健康科技(GSUN.US)$$Laser Photonics(LASE.US)$$Cemtrex(CETX.US)$$Troika Media(TRKA.US)$$NextPlay Technologies(NXTP.US)$$惠普森醫藥(CPHI.US)$$Dianthus Therapeutics(DNTH.US)$$Nuwellis(NUWE.US)$$OpGen(OPGN.US)$$Powerbridge Technologies(PBTS.US)$$Healthcare Triangle(HCTI.US)$$Digital Brands Group(DBGI.US)$$Kintara Therapeutics(KTRA.US)$$Ensysce Biosciences(ENSC.US)$$休斯敦能源(HUSA.US)$$AlTi Global(ALTI.US)$$Zovio(ZVOI.US)$$Agrify(AGFY.US)$$Oblong(OBLG.US)$$SOBR Safe(SOBR.US)$$Nauticus Robotics(KITT.US)$$Avenue Therapeutics(ATXI.US)$$Blue Apron(APRN.US)$$Bright Minds Biosciences Inc(DRUG.CA)$$Applied DNA Sciences(APDN.US)$$智富融資(MEGL.US)$$Evolve Transition Infrastructure(SNMP.US)$$Vivos Therapeutics(VVOS.US)$$American Strategic Investment(NYC.US)$$Icecure Medical(ICCM.US)$$Applied Uv(AUVI.US)$$ShiftPixy(PIXY.US)$$Tempest Therapeutics(TPST.US)$$特百惠(TUP.US)$$Applied Uv(AUVI.US)$$Yield10 Bioscience(YTEN.US)$$Assure(IONM.US)$$Versus Systems(VS.US)$$The Alkaline Water(WTER.US)$$TC BioPharm(TCBP.US)$$Unicycive Therapeutics(UNCY.US)$$Peraso(PRSO.US)$$PARTS iD(ID.US)$$富時新加坡海峽指數(.STI.SG)$$旭日升科技(ASTI.US)$$Abri SPAC I(ASPA.US)$$Connexa Sports Technologies(CNXA.US)$$Unique Fabricating(UFAB.US)$$Aditxt(ADTX.US)$$PainReform(PRFX.US)$$Alpha Technology(ATGL.US)$$Urgent.ly(ULY.US)$$Bruush Oral Care(BRSH.US)$$ReShape Lifesciences(RSLS.US)$$Appreciate Holdings(SFR.US)$ ...
暫無評論